Lesch-Nyhan syndrome (LNS) is a rare X-linked recessive disorder involving purine metabolism caused by the congenital absence of hypoxanthine guanine phosphoribosyl transferase. A characteristic feature of LNS is the appearance of intractable self-injurious behavior, usually in the form of severe lip and finger biting. The mechanism behind this severe self-mutilating behavior is unknown, and is one of the main challenges in the management of this condition. We here report the case of a 30-year-old man with a confirmed diagnosis of LNS who was successfully treated for self-mutilation of his lips with repeated botulinum toxin A (BTX-A) injections in the facial perioral muscles. Our findings suggest that treatment with BTX-A helped reduce self-abusive behavior in this patient. Our case illustrates that BTX-A injections can be a useful therapeutic approach in patients with self-abusive behavior.
L esch-Nyhan Syndrome (LNS) is an Xlinked recessive disorder resulting from the mutation of a gene coding for hypoxanthine guanine phosphoribosyl transferase located in Xq26 and Xq27, 1,2 an enzyme playing a vital role in purine metabolism.
The most striking neurological symptom of this disease is self-mutilation. It is observed in 85% of cases, 3, 4 and is usually vital datum to make a correct diagnosis. 5, 6 Surprisingly, these patients are able to self-mutilate extremely quickly, despite their motor disorders.
This behavior starts at about the age of 2 years together with the time of tooth eruption, and generally decreases at the age of 12 years, together with an increase in the acquisition of self-control skills. It always depends on different conditions, that is, periods of tension or stress, and being in places that are unknown to the patient. 5, 7 Unfortunately, the therapeutic response to self-mutilation is poor; these patients usually require surgical treatment and the removal of the anterior teeth.
The use of mouth guards is not fully effective to minimize the traumatic effects of biting; tooth removal has some complications as the occurrence of progressive cavities.
Despite this limitation, tooth removal has so far been the most effective method to prevent self-mutilation when all the other therapies failed. 8 We here describe the case of a patient with a diagnosis of LNS who was treated with injections of botulinum toxin in the zygomatic, and lip orbicularis and mentalis muscles, which successfully weakened the synergistic muscles used for self-aggression.
The treatment ameliorated self-mutilation behavior and helped heal the injured sites, without affecting chewing.
CASE REPORT
A 30-year-old man, first of 2 twins, borne out of a normal delivery, was admitted to our program of Parkinson's disease and movement disorders with a long-standing history of generalized dystonic posturing, cognitive disturbances, and self-mutilation. Both twins had been diagnosed as having LNS based on biochemical and DNA tests.
At the age of 6 months, delayed psychomotor development as well as abnormal postures was observed.
Progressive mental disturbances were accompanied by generalized increased muscle tone and dystonic movement disorders in the 4 limbs and self-mutilation of his lips and occasionally of other parts of his body.
At the age of 12 years, he was diagnosed as having LNS. Recent studies included uricemia, 6.6 mg% (reference range, 3.5Y7.2 mg%); uricosuria, 1050 mg% (reference range, 250Y750 mg%); glycemia, 113 mg%; urea, 38 mg%; and creatinine clearance, 76 mg/mL. Several medications had been used either as monotherapy or in association, including allopurinol, baclofen, clonazepam; quetiapine, and L-carnitine, which failed to provide significant relief of dystonia or self-injurious behavior.
Several teeth had been removed, but selfmutilation persisted, causing serious lesions leading in turn to infections of the lower lip.
On examination, he was partially oriented to time and space, fundus oculi was normal, and visual fields seemed to be full. Severe dystonic posturing was evident in all 4 limbs as well as in trunk, neck, and facial muscles. He had moderate cognitive impairment, and severe lesions were evident on his lower lip. When he was asked why he wanted to bite his lip, he answered that he knew it was bad for him but he could not refrain from doing it. He said that he could only stop it for a limited period, after which he felt the urge to do it. The rest of the neurological examination was unremarkable.
Pallidal deep brain stimulation (DBS) was suggested, but because surgery was not available immediately and continuous lip chewing required a quick solution, further tooth removal was considered. The possibility that self-injury was a feature of an obsessive-compulsive disorder (OCD) was also entertained, and therapy with serotonin reuptake inhibitors was considered. However, we decided to first inject facial muscles to preclude the lips from getting into the mouth and prevent biting.
We applied injections of botulinum toxin type A (BTX-A; Botox NR) in both zygomatic muscles 12.5 IU each; lower part of the lip orbicularis muscle in 6 injection sites of 2.5 IU each; and levator labii inferioris, 3 injection sites, 5 IU each. The injections were repeated on 2 occasions every 3 months. A few days after the injections, the muscles became hypotonic and weak, and biting ceased with progressive healing of the wounds (see Fig. 1 ). He is currently on a waiting list ready for pallidal DBS implantation.
DISCUSSION
Lesch-Nyhan syndrome is a rare Xlinked recessive disorder of purine metabolism caused by complete absence of the enzyme hypoxanthine-guanine phosphoribosyl transferase. In addition to overproduction of uric acid, neurological manifestations including spasticity, choreoathetosis, mental retardation, and compulsive self-mutilation are the hallmarks of LNS. In the absence of overt self-injurious behavior, the diagnosis may not even be considered. 9 The most common initial mode of self-mutilation and the most frequent behavior is biting of lips and/or fingers. 10 The most typical feature results in partial or total destruction of perioral tissues. Death usually occurs in the second or third decade from renal failure or infection. The cause for the uric acid overproduction has been clarified, but the relationship between the enzyme deficiency and the neurological manifestations in LNS remains unclear.
It has been proposed that the excitatoryinhibitory misbalance in the basal ganglia secondary to the metabolic disruption could result in inadequate modification of the thalamus activity with subsequent mental retardation and symptoms that include the patients not being aware of their own bodies that could give rise to self-mutilation. 11 Alternatively, supersensitivity of the dopaminergic D1 receptors in the neuromatrix found in the cingulum cortex region has also been proposed as the mechanism underlying self-mutilation. 12 Several pharmacological strategies as well as devices such as soft mouth guards to prevent the destruction of perioral soft tissues without tooth removal, the application of restraints, and removal of teeth at an early age or vital pulpotomy and coronal resection 8 have been used with variable degrees of success. 13, 14 The literature is devoid of specific drug therapies or treatments demonstrating significant efficacy in patients with self-injurious behavior.
Several other treatments have been proposed for patients with self-injurious behaviors including dialectical behavior therapy 15 ) for those with bilateral stereotactic amygdalotomy, 16 oxcarbazepine for selfmutilating bulimic patients, 17 psychological strategies like increasing coping mechanisms, facilitating decision-making strategies, encouraging positive relationships, and cultivating self-esteem, 18 but unfortunately, they are seldom useful.
Surprisingly, although dental extractions prevent bite injuries, edentulous patients may later on turn to other forms of self-mutilation using their fingers to injure themselves. 19 Bilateral chronic stimulation (DBS) of the globus pallidus internus, a well-known treatment of diverse forms of dystonia has also proved successful in cases of LNS, not only improving dystonic symptoms, but also self-mutilating behavior, 20 which supports the hypothesis that the neurobehavioral features of this syndrome are either mediated in the basal ganglia pathways or secondary to the dystonia.
Our patient clearly stated that he could suppress the self-injurious behavior by making an effort of will but only for a limited period, after which he would do it again, suggesting an OCD. Severe self-mutilation including autocastration has been reported in patients with OCD. 21 We indicated DBS to our patient but because of bureaucratic issues, the procedure could not be performed as promptly as required, and we decided to inject BTX-A to prevent lip biting.
To our knowledge, only 1 report is available describing the use of BTX-A for the treatment of self-injurious behavior. Dabrowski et al 22 described a 10-year-old boy with LNS who was treated for selfmutilation of his hands, tongue, and lips with repeated BTX-A injections into the bilateral masseters. As in our patient, the lesions mainly involved the lips, so we decided to inject the facial muscles to prevent biting rather than injecting the masseters because the latter require larger doses of toxin, which in turn could spread to pharyngeal muscles affecting dysphagia.
During the next weeks, lip biting had markedly decreased, and the lesion began to heal. We repeated the injections every 3 months with marked benefit in the selfinjurious behavior. No side effects were observed, and the patient did not develop an alternative self-mutilating behavior.
Our case illustrates that BTX-A injections can be a useful therapeutic approach in patients with self-mutilating behavior. Furthermore, it demonstrates that small doses of BTX-A injected in the facial muscles rather than higher doses in masticatory muscles are useful to prevent this conduct when it is limited to perioral muscles.
